India Plasma Fractionation Market Size, Share & Industry Analysis, By Product (Albumin, Immunoglobulin, and Coagulation Factors {Factor VIII, Factor IX, and Others}), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, and Others), By End-user (Hospitals & Clinics, Research Organizations, and Others), and Regional Forecasts, 2025-2032

The India plasma fractionation market size was valued at USD 383.5 million in 2024. The market is projected to grow from USD 400.5 million in 2025 to USD 606.1 million by 2032, exhibiting a CAGR of 6.1% during the forecast period.

The India plasma fractionation market is emerging as an important segment driven by rising demand for plasma-derived therapies such as immunoglobulins, albumin, and coagulation factors. Additionally, the increasing number of patients suffering from burns, shocks, and trauma has heightened the need for plasma components due to massive blood loss. As the demand for these plasma components increases, the fractionation used to separate plasma proteins is gaining momentum in India.

• For instance, in June 2023, PlasmaGen Biosciences inaugurated a new manufacturing facility for plasma-derived protein therapeutics at Kolar, Bengaluru, India. The facility aims to produce multiple plasma-derived products such as albumin, immunoglobulins, and coagulation factors.

While the nation remains significantly dependent on imports for plasma products, domestic players are expanding capacity with government policy support and technological partnerships, positioning the India plasma fractionation market for steady growth.

The market is anticipated to experience significant growth in the upcoming years due to various factors such as the growing prevalence of chronic diseases, increasing surgical applications, and rising demand for critical care. Many key industry players, such as Reliance Life Sciences, PlasmaGen BioSciences Pvt. Ltd., and Intas Pharmaceuticals Ltd., are operating in the market. These companies are focusing on expanding their fractionation capacity with new facility launches to support the growing India plasma fractionation market demand.

MARKET DYNAMICS

MARKET DRIVERS

Rising Burden of Hematological Diseases to Accelerate Market Growth

The increasing prevalence of hematological disorders such as hemophilia, von Willebrand disease, and other clotting factor deficiencies is a major driver of plasma fractionation demand in India. Patients with these conditions rely on plasma-derived therapies for effective disease management. In addition, the rise in complex surgical procedures and trauma cases further boosts the need for plasma-derived clotting support. India’s significant demand-supply gap in plasma products is amplifying growth opportunities for domestic manufacturers. As the burden of hematological diseases continues to grow, the dependency on therapeutic plasma components will intensify, accelerating India plasma fractionation market growth.

• For instance, in August 2020, Intas Pharmaceuticals Ltd., through its research & development team, developed a COVID-19-specific Hyperimmune Globulin for the treatment of patients suffering from moderate to severe COVID-19 infection. This product served as an important therapeutic option to help combat COVID-19 until a vaccine became available in India.

MARKET RESTRAINTS

Limited Plasma Collection Infrastructure to Impede Market Growth

A weak foundation in plasma collection infrastructure restrains India’s plasma fractionation potential due to limited plasma donation. With few dedicated source plasma centers and a reliance primarily on plasma-derived products from whole-blood donations, the raw supply remains fragmented and unstable. Many blood banks lack the equipment, staff, or cold-chain logistics to separate, store, and transport plasma safely. As a result, much of the potential donor plasma is either lost, underutilized, or degraded before reaching fractionation units. These factors result in a constrained feedstock stream, which raises unit costs, limits scalability, and deters further investment in fractionation facilities. Furthermore, inconsistent or inadequate infrastructure across rural and remote areas creates regional imbalances in supply, with some centers having excess plasma, while others face chronic shortages, thereby undermining the reliability of a national network. Over time, this bottleneck forces domestic fractionators to depend on imports or operate below capacity, weakening the overall competitiveness of the India plasma fractionation market.

• For instance, in April 2022, Virchow Biotech Pvt Ltd. received approval from the Indian central government to develop a drug for immunoglobulin for the treatment of COVID-19, but faced plasma shortages from recovered patients.
• In June 2020, Printline Media Pvt. Ltd. published an article that reported India wastes approximately 6.5 lakh units of blood and blood components on an annual basis.

MARKET OPPORTUNITIES

Technological Advancement to Provide Significant Market Growth Opportunities

The current technology implemented for blood fractionation requires a longer processing time. Technological advancements that significantly reduce this time and minimize contamination risks offer lucrative growth opportunities. These innovations increase protein recovery rates, reduce processing time, and enhance product safety, which in turn lowers overall production costs by overcoming the limitations of older methods. This technological shift makes domestic production more competitive against imports and supports regulatory compliance with global quality standards. As a result, firms investing in modern fractionation infrastructure are well-positioned to capture a larger share of the growing demand for plasma-derived therapeutics.

• For instance, in May 2025, scientists from the Indian Institute of Information Technology, Allahabad, created a cost-effective plasma fractionation device capable of performing plasma fractionation within minutes.

INDIA PLASMA FRACTIONATION MARKET TRENDS

Strategic Collaboration and Acquisition is a Prominent Trend Observed in the Plasma Fractionation Market

One of the prominent trends observed in the India plasma fractionation market companies is the pursuit of strategic collaborations, partnerships, and acquisitions to strengthen their technological capabilities. These acquisitions expand product portfolios and reduce dependency on imports. These partnerships enable faster technology transfer, ensure regulatory compliance, and allow companies to address the rising demand for immunoglobulins, albumin, and clotting factors more efficiently. Acquisitions allow firms to consolidate resources, optimize costs, and expand geographic reach in a highly competitive market.

• For instance, in August 2025, Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, acquired Prothya Biosolutions Belgium BV and each of its subsidiaries. The development positioned the company as a leading plasma-derived medicinal products (PDMP) business.

MARKET CHALLENGES

High Cost of Compliance and Regulatory Burden Pose a Critical Challenge to Market Growth

Plasma fractionation is a highly regulated process that requires strict adherence to pathogen safety, viral inactivation, cold chain maintenance, and international quality standards. For Indian manufacturers, complying with these requirements involves significant investment in advanced testing laboratories, GMP-certified facilities, and the continuous validation of processes. Additionally, evolving global guidelines and India’s alignment with the WHO and European regulatory frameworks mandate companies to upgrade equipment and processes, adding to frequent recurring expenditure. This high compliance cost raises barriers to entry and slows the pace of domestic capacity expansion, making India more reliant on imports for advanced plasma-derived products.

• For instance, in September 2025, The Times of India reported that the Drug Marketing and Manufacturing Association sought government intervention, citing the shutdown of more than 5000 units across the country due to increased regulatory burden. The association urged the withdrawal of the directive mandating bioequivalence studies.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product

Increasing Prevalence of Immunodeficiencies to Boost Immunoglobulin Segment Growth

Based on product, the market is divided into albumin, immunoglobulin, and coagulation factors.

The immunoglobulin segment is projected to dominate the India plasma fractionation market. The segment has diverse applications across immune deficiency, autoimmune, infectious, and neurological diseases, making it one of the fastest-growing plasma-derived product segments in India. Due to their critical role in primary immunodeficiencies, replacement therapy, autoimmune and inflammatory conditions such as Guillain–Barré syndrome, immunoglobulins are driving expansion into chronic care settings. Moreover, India’s rising participation in global clinical research and trials involving IVIG is further expanding its usage, making this segment a key driver of the plasma fractionation market.

• For instance, in December 2022, the International Journal of Scientific Reports published an article titled ‘Disease profile of Guillain-Barré syndrome among Indian patients receiving intravenous immunoglobulin: a real-world observational study,’ that which evaluated and reported a high usage pattern of intravenous immunoglobulin (IVIG) for the treatment of patients with Guillain‐Barré syndrome (GBS).

By Application

Increasing Application of Plasma in Immunology & Neurology to Bolster the Segment’s Growth

By application, the market is segmented into immunology & neurology, hematology, critical care, pulmonology, and others.

The immunology & neurology segment held the maximum portion of the market. In 2025, the segment is anticipated to dominate with a 53.9% share. In immunology and neurology, immunoglobulins are critical for controlling immune responses and neutralizing pathogenic antibodies. Their vital role in neurological diseases such as Guillain–Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and in autoimmune diseases such as hypoalbuminemia cytopenias, systemic lupus erythematosus, is indispensable. Immunoglobulins are used to suppress harmful autoantibodies and control inflammation.

• For instance, in April 2024, NIH published a study titled ‘The Relationship Between Serum Albumin Levels and Sepsis in Patients Admitted to a Tertiary Care Center in India’ which reported results of a study conducted among 102 ICU patients. Hypoalbuminemia was present in 56.9% ( 58) of the patients.

The hematology segment is expected to grow at a CAGR of 6.3% over the forecast period.  

By End-user

Increasing Incidence of Trauma to Boost Hospitals & Clinics Segment Growth

Based on end-user, the market is segmented into hospitals & clinics, research organizations, and others.

In 2024, the hospitals & clinics segment is expected to capture the highest India plasma fractionation market share during the forecast period. The segment serves as the primary distribution point for plasma-derived therapeutics used in critical and chronic care. With the rising incidence of trauma, burns, surgical interventions, liver and bleeding disorders, hospitals increasingly depend on albumin, immunoglobulins, and coagulation factors to manage emergencies and long-term treatments. Furthermore, the segment is set to hold 85.3% share in 2025.

• For instance, in December 2024, NIH published a report titled ‘Plasma transfusion in the intensive care unit. It includes results from the study of 3643 patients, among whom 356 patients (10%) experienced 547 plasma transfusion events, accounting for 18% of total transfusion events. Such high utilization of plasma in hospital care reinforces the dominance of the hospitals & clinics segment in the market.

In addition, research organizations as end-users are projected to grow at a CAGR of 5.6% during the study period.

COMPETITIVE LANDSCAPE

Key Industry Players

Major Players Focus on Product Development to Boost Their Market Position

The India plasma fractionation market shows a consolidated structure with a small number of large-sized companies actively operating across the globe. These players collect and fractionate plasma for future therapeutic applications.

PlasmaGen BioSciences Pvt. Ltd, Intas Pharmaceuticals Ltd, and Reliance Life Sciences are some of the dominating players in the market. These companies have a strong foothold in the market and participate in strategic activities such as facility launches to support the increasing demand for plasma in India.

Apart from this, other prominent players in the market include Serum Institute of India Pvt. Ltd., VIRCHOW BIOTECH, in the market. These key players are focusing on the fractionation and marketing of plasma therapeutics with a significant focus on innovative product development to enhance their market presence.

LIST OF KEY INDIA PLASMA FRACTIONATION COMPANIES PROFILED

• PlasmaGen BioSciences Pvt. Ltd. (India)
• Reliance Life Sciences (India)
• VIRCHOW BIOTECH (India)
• Intas Pharmaceuticals Ltd. (India)
• Promea Therapeutics (India)
• Ichor Biologics (India)

KEY INDUSTRY DEVELOPMENTS

• June 2025: Promea Therapeutics Pvt. Ltd. signed a Memorandum of Understanding (MoU) with Sri Sathya Sai Institute of Higher Learning (SSSIHL) expanding collaboration between healthcare and biopharmaceutical This partnership aimed to strengthen the institute’s industry-academia interface and advancing translational research in life sciences sector.
• December 2023: PlasmaGen Biosciences raised USD 26.9 million from U.K.-based Artian Investments to expand its presence internationally, develop plasma products, and fund working capital requirements.
• July 2025: Ichor Biologics Private Limited expanded its facility in Medchal-Malkajgiri district, Telangana, India. The facility is spread over Spread over 1.75 lakh sq. ft. The development aims to position Telangana as a global hub for the plasma fractionation market and to expand the production facility of the company.
• August 2020: Intas Pharmaceuticals Limited developed and launched a COVID-19-specific Hyperimmune Globulin for the treatment of patients suffering from moderate to severe COVID-19 infection. The product also showed potential as a prophylaxis therapy for high-risk populations exposed to COVID-19 patients. The company was the first to launch 4 plasma products in the country.
• June 2021: Ichor Biologics Private Limited acquired Hemarus Therapeutics Ltd., a plasma-derived biopharmaceuticals company. The acquisition enabled the transfer of drug licenses from Hemarus to Ichor for therapeutic protein products such as immunoglobulin, albumin, coagulation factors, and fibrin sealant kit used in plasma protein therapy.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation